Law360, New York (February 02, 2009, 12:00 AM ET) -- In yet another challenge to reverse payment settlements, the state of California and the Federal Trade Commission have filed a lawsuit against several pharmaceutical companies, claiming their patent lawsuit settlements over the testosterone supplement AndroGel violate U.S. antitrust laws.
The lawsuit filed in the U.S. District Court for the Central District of California and announced by the FTC on Monday alleges that settlements Watson Pharmaceuticals Inc., Par Pharmaceutical Cos. Inc. and Paddock Laboratories reached with Solvay Pharmaceuticals Inc. that included agreements not to market generic versions...
FTC, Calif. Launch Reverse Payment Challenge
To view the full article, take a free trial now.
